EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer

被引：0
|
作者：
Ueno, Naoto [1 ]
LaFortune, Tiffany [1 ]
Hortobagyi, Gabriel [1 ]
Lucci, Anthony [1 ]
Singh, Balraj [1 ]
Krishnamurthy, Savitri [1 ]
Esteva, Francisco [1 ]
Hung, Mien-Chie [1 ]
Zhang, Dongwei [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1767
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
    Montemurro, Filippo
    Valabrega, Giorgio
    Aglietta, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 257 - 268
  • [32] MAPK signaling is involved in intrinsic and acquired resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
    Normanno, N.
    Maiello, M. R.
    De Luca, A.
    Carotenuto, A.
    Rachiglio, A. M.
    D'Alessio, A.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [33] Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
    Luo, Jia
    Makhnin, Alex
    Tobi, Yosef
    Ahn, Linda
    Hayes, Sara A.
    Iqbal, Afsheen
    Ng, Kenneth
    Arcila, Maria E.
    Riely, Gregory J.
    Kris, Mark G.
    Yu, Helena A.
    JCO PRECISION ONCOLOGY, 2021, 5 : 55 - 64
  • [34] Phase II study of single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent Glioblastoma Multiforme
    Vogelbaum, Michael A.
    Peereboom, David
    Stevens, Glen H.
    Barnett, Gene H.
    Brewer, Cathy
    ANNALS OF ONCOLOGY, 2004, 15 : 206 - 207
  • [35] ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
    A J Ryan
    S R Wedge
    British Journal of Cancer, 2005, 92 : S6 - S13
  • [36] Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells
    Wu, Yushan
    Zhang, Dongxing
    Wu, Baofan
    Quan, Yuan
    Liu, Dongwu
    Li, Yanyan
    Zhang, Xiuzhen
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2017, 65 (08) : 768 - 775
  • [37] Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    Mukherjee, A.
    Dhadda, A. S.
    Shehata, M.
    Chan, Stephen
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) : 2189 - 2204
  • [38] Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
    Paul, Betsy
    Trovato, James A.
    Thompson, Jennifer
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (18) : 1703 - 1710
  • [39] Adsorption and desorption of tyrosine kinase inhibitor erlotinib on gold nanoparticles
    Anh Thu Ngoc Lam
    Yoon, Jinha
    Ganbold, Erdene-Ochir
    Singh, Dheeraj K.
    Kim, Doseok
    Cho, Kwang-Hwi
    Son, Sang Jun
    Choo, Jaebum
    Lee, So Yeong
    Kim, Sehun
    Joo, Sang-Woo
    JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2014, 425 : 96 - 101
  • [40] Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
    Johnston, Stephen R. D.
    Leary, Alex
    DRUGS OF TODAY, 2006, 42 (07) : 441 - 453
12345